Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Information for patients and caregivers on how to manage adverse events from immune checkpoint inhibitors
Stay in touch with your cancer care team about how the new pandemic will affect you and your treatment.
Checkpoint inhibitor extended survival by about three months compared with chemotherapy.
Initial treatment with atezolizumab led to longer overall survival in people with high biomarker levels.
The combination led to improved overall survival compared with chemotherapy.
“While our results are promising, a key limitation to this approach is that approximately 60 percent of patients still did not respond."
A study of melanoma patients found that treatment every six weeks is comparable to every three weeks.
A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.
It’s possible to identify these individuals in advance, helping them to focus on clinical trials of more effective treatments.
Researchers attribute this promising shift to the introduction of nearly a dozen new treatments for this form of skin cancer.
“I felt any small contribution I might make for sarcoma patients could have a huge impact on them and the way the disease is treated.”
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.